LONGMONT, CO -- (Marketwired) -- 05/23/14 -- MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that it has approved the final formulation as well as product branding for its new line of dissolvable oral medical cannabis "Medi-Strips."
Fast dissolving films are gaining interest as an oral delivery alternative to tablets and pills. The mint flavored Medi-Strips films are designed to dissolve upon contact with a wet surface, such as the tongue, allowing the patient to take the product without need for additional liquid. As the drug is directly absorbed into systemic circulation, degradation in gastrointestinal tract and first pass effect can be avoided. This convenience factor provides both a marketing advantage and increased patient compliance. Over-the-counter films for pain management and motion sickness have already been successfully commercialized in the US markets and mainstream consumer acceptance increases daily. Combining medical cannabis with this delivery system gives the user a discreet, controlled dose of nighttime pain relief without any oral ingestion complications that can often afflict terminal patients.
"We are absolutely elated to be providing such an innovative and cutting edge delivery system for cannabinoids. Our thin film medicated strips are an orally absorbed, fast acting, dissolvable medical cannabis delivery platform that will provide patients quick and long lasting pain relief. I am also excited about the extensions into tertiary demographics, such as geriatrics where oral ingestion and choking hazards are common place. I believe this product will have mainstream, as well as, targeted appeal throughout the medical cannabis marketplace," commented Dr. Joseph Cohen, Chief Medical Officer of MediJane Holdings.
Spike Humer, Chairman of MediJane, concluded, "With all development aspects of this new product line complete, we are very eager to get MediJane Medi-Strips into customer hands quickly wherever legal medical cannabis is sold. This product launch solidifies the direction we are headed in as a company which is to provide medical cannabis to patients utilizing the most innovative, accurate, and reliable delivery systems available."
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead products, the innovative non-drowsy "Daytime Pain plus CBD" oral capsule and the Canna-Mist cannabinoid spray, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.